The Evolution of T-cell Therapies for Solid Malignancies

Kristen Fousek1,2,3,4 and Nabil Ahmed1,2,3,4

Abstract

Primary resistant, recurrent, and relapsed solid tumors are often nonresponsive to conventional antineoplastic therapies. Moreover, in responsive tumors, the therapeutic-to-toxic range of these interventions remains quite narrow, such that side effects of therapy are substantial. Targeted therapies, such as adoptive T-cell transfer, not only spare normal tissues but also use alternative killing mechanisms to which the tumor cells are usually not immune. Adoptive T-cell transfer for solid tumors faces unique challenges because of the inherent heterogeneity of tumor parenchyma, the complexity of the tumor microenvironment, and tumor occurrence in areas with limited therapeutic accessibility. In this review, we examine the recent evolution of various T-cell-based immunotherapeutics, the mechanisms of action behind their antitumor activity, their increasing complexity, and the prospect of building on previous successes in the treatment of solid tumors.

Disclosure of Potential Conflicts of Interest

The Center for Cell and Gene Therapy has a research collaboration with Celgene to develop chimeric antigen receptor (CAR)-based therapeutics that is administered by Baylor College of Medicine. N. Ahmed is listed as an inventor on patent applications in the field of T-cell and gene-modified T-cell therapy for cancer. No potential conflicts of interest were disclosed by the other author.

Editor’s Disclosures

The following editor(s) reported relevant financial relationships: J.R. Grandis—None.

Learning Objectives

Upon completion of this activity, the participant should have a better understanding of the challenges specific to the treatment of solid tumors, the rationale underlying the development of T-cell immunotherapies, and the mechanisms by which novel T-cell therapies and combination immune therapies lead to antitumor activity.

CME Staff Planners’ Disclosures

The members of the planning committee have no real or apparent conflicts of interest to disclose.

Acknowledgment of Financial or Other Support

This activity does not receive commercial support.

Introduction

Early-stage solid cancers, defined as solid malignancies of non-lymphoreticular origins, are fairly well controlled using standard-of-care therapies. Resistant, metastatic, or recurrent tumors are often surgically unresectable and are frequently nonresponsive to further radiation or chemotherapies. Recently, alternative strategies, including immunotherapies using selected or engineered T cells, have shown promise in the treatment of blood cancers.

Immunotherapies are of particular interest in solid malignancies because of the peculiar interaction between the immune system and the tumor complex (1). The immune system acts in duality by providing antitumor activity via CD8+ and CD4+ T cells and their immune activating cytokines while conversely shielding the tumor from death through the activity of T regulatory cells and their immunosuppressive cytokines. There are various modalities of T cell–based therapies that rely on the T cells’ ability to recognize and kill aberrant cells (Table 1). T-cell therapies for solid tumors, however, face a number of unique challenges. Here, we discuss the evolution of adoptive T-cell transfer, from the simplest forms to the more recent and more sophisticated approaches used to overcome the immune-evasion strategies of solid tumors.
T-cell Transfer: The Promise

For those tumors that traditional therapeutics have failed, alternative strategies are needed. Based on recent insight into tumor biology and immunology, harnessing a patient’s own immune system to enhance treatment has become an increasingly attractive option. Adoptive cell therapy (ACT) is the process by which immune cells are transferred to a recipient to induce an antitumor effect (2). T cells are capable of homing to tumor sites throughout the body, providing an advantage for use in ACT over antibodies, which neither effectively cross the blood–brain barrier nor consistently achieve adequate biodistribution deep inside solid tumors. Theoretically, T cells are capable of inducing a response powerful enough to mediate meaningful antitumor regression. T cells can be enriched from tumor-specific precursors and/or modified to possess a predetermined antigenic specificity and can be expanded ex vivo to clinically relevant numbers. Moreover, adoptive T-cell transfer could provide a long-lasting therapeutic effect following a small number of treatments if a memory subset of T cells is successfully attained. The arduous and expensive production process, mostly restricted to autologous T-cell products, is an important disadvantage to T-cell therapies and an impediment to their commercialization. However, recent efforts have led to simplification of the production processes (3) as well as exploration of third-party lines (NCT02108522), enabling T-cell therapy to become an "off-the-shelf" therapy to a greater extent.

Tumor-infiltrating lymphocytes (TIL) were the earliest effective form of T-cell transfer for solid tumors (Table 2). TILs are isolated from tumor tissue, expanded ex vivo in IL2, and systemically administered to patients with lymphodepleted advanced melanoma (4). TILs maintain specificity to tumor antigens and are capable of recognizing intracellular antigenic peptides presented within the context of the MHC-I/T-cell receptor (TCR; ref. 5; Table 3). Objective clinical responses in 50% to 70% of patients (6), and even complete tumor regression in 22% of patients with metastatic melanoma (7), launched a new era of efficacious T-cell therapy for solid tumors. Recently, T cells have been further modified with homing receptors, demonstrating enhanced localization to tumor sites in preclinical melanoma studies (8). These promising data have led to the development of a clinical trial using modified TILs for the treatment of metastatic melanoma (NCT01740557).

Although TILs have shown promise in melanoma patients, cytotoxic T lymphocytes (CTL) yield promising results in patients with virus-associated malignancies (Table 2). CTLs can be effectively isolated from the peripheral blood, then enriched or rendered tumor specific ex vivo. Following infusion, CTLs engage the TCR with a target antigen–derived peptide presented on MHC-I molecules, resulting in T-cell activation and antitumor activity (Table 3). Ex vivo–generated Epstein–Barr virus (EBV)–specific CTLs have been used for the treatment of post-transplant lymphoproliferative disease, nasopharyngeal carcinoma (NPC), and lymphoma with varied success (9–11). Similarly, cytomegalovirus (CMV)-specific CTLs have been efficacious in CMV-infected autologous glioblastoma in preclinical work (12) and have been explored in clinical trials for glioblastoma (NCT01109095, NCT01205334, and NCT00693095; Tables 1 and 2; ref. 13).

Although adoptive transfer of TILs and CTLs has shown promise, their broader application has been quite limited. There are prohibitive difficulties in isolating and expanding TILs, which are present at the tumor site at very low frequency (14). In fact, the success of TIL transfer has been limited largely to malignant melanoma (6, 7). Although CTLs are more extensive in their application than TILs, their tumor-associated antigen (TAA) recognition is MHC restricted. MHC restriction is a major limitation, as the majority of solid tumors use immune escape mechanisms, such as altering their MHC expression and TAA processing (15). Genetically engineered T cells have emerged as an alternative to TIL and CTL therapies, overcoming some of the challenges associated with solid tumors.

T-cell Engineering: The Next Generation

Engineering T cells to recognize and target specific TAAs has been achieved through the production of transgenic T-cell receptors (tgTCR) and chimeric antigen receptors (CAR; Table 3). These
tgTCRs are produced by introducing genetic information encoding α and β chains of a TCR with specificity to a TAA into activated T cells (16). Tumor-specific T cells are first isolated from a patient. After expansion, the genes encoding TAA-specific TCRs can be isolated, cloned, and transduced into T cells isolated from the patient’s peripheral blood (16, 17). These T cells with optimal TCRs can be expanded in vitro and subsequently administered to the patient. The tgTCRs redirect T cells to target extracellular or intracellular TAAs by pairing with the endogenous CD3 complex and activating T-cell signaling upon encounter of their respective antigen presented by MHC. Autologous T cells transduced with a TCR specific to NY-ESO-1 resulted in objective clinical responses in 60% of patients with synovial cell sarcoma and 45% of patients with melanoma (17, 18). This approach, nevertheless, faces some substantial challenges. First, the affinity of the TCR to its peptide/MHC complex can greatly affect efficacy. If the TCR has low affinity or the tumor downregulates MHC expression, tgTCR T cells become ineffective. Second, the combination of human leukocyte antigen (HLA) alleles expressed by various individuals is expansive, making it imperative to either produce tgTCR T cells for each individual patient or develop a vast library of cells capable of recognizing TAAs within the MHC context of many different HLA types. Because this is unrealistic, tgTCR T cells have been limited primarily to HLA-A2 individuals (16). Finally, some studies have demonstrated the ability of the transgenic α and β chains to “mis-pair” by forming heterodimers with native TCR chains (19). Strategies under investigation to circumvent these limitations include structural modifications of TCRs (20–22). transduction of γδ T cells (23) or hematopoietic stem cells (HSC) later differentiate into T cells, CTLs, or other immune effectors using a variety of transfer technologies (16). CAR functionality differs radically from traditional or transgenic T cells in that target recognition is MHC unrestricted (27). CAR exodomain/TAAs binding is thought to be comparable to the dynamics of antibody binding in both avidity and orientation. Although the exact activation mechanism is not known, it is thought that CARs activate canonical signaling pathways mediated by moieties present in their intracellular signaling domain (27).

CAR T-cell investigations began by treating hematologic malignancies, partly because the lineage-restricted surface expression of antigens was better understood and modified T cells could be more easily delivered to tumor sites within the blood. One of the most successfully targeted antigens to date is cluster of differentiation 19 (CD19). Currently 27 active clinical trials are using CAR-based immunotherapies for the treatment of CD19⁺ hematologic cancers (28). In contrast with the major successes in hematologic malignancies, the impact of CAR T cells in solid tumors remains limited. The most primitive CARs yielded short-lived antitumor activity, prompting studies addressing the role of cytokines (27), the importance of T-cell subset and phenotype (27), and the design of CARs capable of providing costimulatory signals required for complete T-cell activation (29).

Table 2. Examples of clinical studies using various T-cell-based therapies for the treatment of solid tumors

<table>
<thead>
<tr>
<th>Target</th>
<th>Solid tumor therapy</th>
<th>Reported responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>TILs</td>
<td>Putative melanoma antigens</td>
<td>Autologous TILs in patients with metastatic melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T cells transduced with CXCR2 to enhance homing or NGFR for metastatic melanoma</td>
</tr>
<tr>
<td>CTLs</td>
<td>CMV immunodominant antigen pp65</td>
<td>CMV-specific CTLs in patients with GBM</td>
</tr>
<tr>
<td></td>
<td>EBV antigens LMP/2, EBNA1/2, EBNA5/2</td>
<td>EBV-specific CTLs in patients with nasopharyngeal carcinoma</td>
</tr>
<tr>
<td></td>
<td>TgTCR NY-ESO-1</td>
<td>Autologous TCR-transduced T cells in patients with synovial cell carcinoma and melanoma</td>
</tr>
<tr>
<td></td>
<td>CEA</td>
<td>Autologous TCR-transduced T cells for patients with colorectal cancer</td>
</tr>
<tr>
<td>CAR</td>
<td>HER2</td>
<td>CMV-specific CTLs expressing HER2 CAR in patients with GBM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HER2 CAR and TGFβ resistant CTLs in patients with HER2⁺ malignancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autologous HER2 CAR T cells in patients with osteosarcoma (HEROS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autologous HER2 CAR T cells in patients with sarcoma after fludarabine/cyclophosphamide lymphodepletion (HEROS 2.0)</td>
</tr>
<tr>
<td>IL13Rα2/GD2</td>
<td>IL13Rα2 CAR CDB⁺ CTLs in patients with high-grade glioma</td>
<td>IL13Rα2 CAR CDB⁺ CTLs in patients with high-grade glioma</td>
</tr>
<tr>
<td></td>
<td>GD2</td>
<td>GD2 CAR expressed in activated T cells or EBV-CTLs in patients with neuroblastoma</td>
</tr>
<tr>
<td></td>
<td>Mesothelin</td>
<td>Mesothelin CAR T cells in patients with metastatic mesothelin⁺ cancer</td>
</tr>
<tr>
<td>Engager T cells</td>
<td>EGFRvIII</td>
<td>EGFRvIII CAR T cells in patients with glioma</td>
</tr>
<tr>
<td>None to date</td>
<td>None to date</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DC, dendritic cell; GBM, glioblastoma; NGFR, nerve growth factor receptor.
<table>
<thead>
<tr>
<th>Cell product</th>
<th>Generation</th>
<th>Mechanism</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Enhancements</th>
</tr>
</thead>
<tbody>
<tr>
<td>TILs</td>
<td>Natural T cells isolated from autologous tumor tissue and cytokine expanded \textit{ex vivo}</td>
<td>Native TCR recognizes processed TAA peptides presented on MHC-I molecules</td>
<td>Recognize intracellular and extracellular antigens</td>
<td>Difficult to isolate and expand</td>
<td>TILs expressing chemokine receptors to enhance homing</td>
</tr>
<tr>
<td></td>
<td>Surgical sample</td>
<td>Broad TAA specificity</td>
<td>MHC-restricted</td>
<td>Low frequency of TAA specific cells</td>
<td>Autoimmunity due to shared epitopes</td>
</tr>
<tr>
<td></td>
<td>TIL product</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTLs</td>
<td>Natural circulating tumor specific T cells enriched and expanded \textit{ex vivo} from the patient's peripheral blood using APCs</td>
<td>Native TCR recognizes processed TAA peptides presented on MHC-I molecules</td>
<td>Specific to viral or nonviral TAA</td>
<td>MHC-restricted</td>
<td>Use of third-party donor CTLs</td>
</tr>
<tr>
<td></td>
<td>CTL product</td>
<td>Take advantage of T_{h} and APC augmentation of survival and persistence \textit{in vivo}</td>
<td>Low affinity of TAA TCR</td>
<td>Low frequency of TAA specific cells</td>
<td>Limited efficacy in nonviral TAA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued on the following page)
Table 3. Modalities of T-cell therapy (Cont’d)

<table>
<thead>
<tr>
<th>Cell product</th>
<th>Generation</th>
<th>Mechanism</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Enhancements</th>
</tr>
</thead>
<tbody>
<tr>
<td>tgTCR T cells</td>
<td>Engineered T cells expressing an optimized transgenic TCR with specificity to TAAs</td>
<td>tgTCR recognizes processed TAA presented on MHC-I molecules</td>
<td>Target extracellular or intracellular TAAs</td>
<td>MHC-restricted</td>
<td>Affinity matured tgTCR T cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Enhanced specificity</td>
<td>Mis-pairing with native TCR</td>
<td>DNR to resist TGFβ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Usually restricted to HLA-A2 patients</td>
<td>Rare recognition of native antigens</td>
<td>Expression in a γδ T cells or HSC platform</td>
</tr>
</tbody>
</table>

CAR T cells: T cells engineered to express a CAR, an artificial molecule with a TAA-specific scFv exodomain and a ζ-chain intracellular domain

CAR exodomain recognizes intact TAA through the stereo-electrical properties of the exodomain (similar to a mAb Fv) | MHC-unrestricted | Largely restricted to extracellular antigens | Affinity matured CAR molecules |
|              | CAR exodomain | Reliably produced | Massive T-cell proliferation results in CRS | Conditional CAR T cells |
|              | High frequency of TAA specificity | Massive T-cell proliferation results in CRS | Multispecific CAR molecules, TanCAR |
|              | Tumor | DNR to resist TGFβ | Safety switches |

Abbreviations: APC, antigen-presenting cell; CRS, cytokine release syndrome; DNR, dominant negative receptor; MHC-I, major histocompatibility class I; Mo, monocyte; PBMC, peripheral blood mononuclear cells; Tα, helper T cells.

NOTE: Natural components are gray, transgenic components are black, and tumor targets are red.
Although the expression of tgTCRs or CARs has greatly expanded the therapeutic reach of adoptively transferred T cells, neither strategy takes advantage of resident T cells. The adoptive transfer of ex vivo–manipulated resident T cells (TIL) has been quite transformational in melanoma. Thus, interest in how to additionally redirect the specificity of T cells already present within the tumor microenvironment has grown (Table 1).

Redirecting Resident T Cells to TAAs

Resident T cells represent a potentially powerful source of immune effectors readily available within the tumor. A number of technologies to harness these cells as a source of antitumor activity have been explored. Several bispecific antibody platforms have been developed to redirect T-cell activity to TAAs. The fusion of two single-chain variable fragments (ScFv) via a flexible linker peptide yields tandem ScFvs (TaFv), chimeras that provide the minimal protein sequence needed for antigenic recognition as well as the flexibility necessary to enable interaction with multiple targets (30). TaFv molecules can be designed to target any two antigens that may exist within close proximity to each other and may also be utilized to target an antigenic peptide and simultaneously activate an immune response. The latter approach has exhibited promising results: TaFv molecules have been engineered to include specificity to the TCR molecule CD3 as well as a TAA, termed bispecific T-cell engagers (BiTE). BiTES can redirect polyclonal T cells within the tumor to elicit a TAA-specific response, potentially activating multiple cycles of target cell killing (30). Most notably, a phase I clinical trial using MT110, a CD3/EpCAM (epithelial cell adhesion molecule) BiTE for the treatment of solid tumors, including lung, gastric, colorectal, breast, prostate, and ovarian cancers, was recently completed (NCT00635596). The results of this study have not yet been published. Moreover, as shown in preclinical studies, BiTE-secreting T cells, or engager T cells, take advantage of the innate avidity of T cells for the tumor site and locally secrete CD3/EphA2 (ephran type-A receptor 2) BiTES, redirecting bystander T cells to the EphA2 TAAs expressed in glioma and lung cancer models (31).

A significant amount of research has focused on enhancing the activated T-cell response against tumor cells. Each of these technologies resulted in varied success in preclinical and clinical studies of solid tumors. Such differential results inspired further investigation of challenges associated specifically with solid tumors, as well as ways to overcome the tumor microenvironment and the immunosuppressive activity of regulatory T cells.

Challenges Specific to Solid Tumors

Solid tumors typically exhibit a highly heterogeneous landscape of TAAs, promoting antigen escape. Moreover, solid tumors are supported by a complex microenvironment capable of suppressing the immune response and are often found in areas within the body that are difficult to access for treatment. These complexities mean that progressively more sophisticated T-cell products are necessary for the treatment of solid tumors.

Solid tumor heterogeneity and strategies to offset antigen escape have been a particular interest of ours. Bispecific T cells expressing distinct CARs for both human epidermal growth factor receptor 2 (HER2) and interleukin-13 receptor subunit alpha-2 (IL13Rα2), two highly prevalent glioblastoma antigens, were able to offset antigen escape, enhance T-cell activation, and provide a significant overall survival advantage in an orthotopic mouse model (32). Proof-of-concept experiments demonstrated the feasibility of targeting multiple TAAs simultaneously using a single CAR molecule with an exodomain incorporating two antigen recognition moieties joined in tandem (TanCAR; ref. 33). TanCAR T cells can target each antigen individually and provide synergetic T-cell activation upon encounter of both antigens (33). This CAR design was expanded to include elements from the tumor microenvironment as well as a tumor antigen (34), yielding a broad-spectrum product. Targeting a tumor profile rather than a specific TAA could represent a more viable strategy to control solid tumors.

T cells face a hostile tumor microenvironment featuring immunosuppressive molecules such as transforming growth factor β (TGFβ) and IL10. The development of a dominant negative TGFβ receptor (DNR; a human TGFβ receptor with a truncated endodomain) has conferred T cells with resistance to TGFβ (35). Autologous HER2+ DNR EBV CTLs are currently being tested in phase I/II trials for HER2-expressing malignancies (NCT00889954). Converting an immunosuppressive signal into a positive signal has also been pursued to actively enhance the proliferation of transduced T cells. An artificial molecule composed of the exodomain of the antiproliferative Th2 cytokine, IL4, fused to the endodomain of the Th1 proliferative cytokine, IL7, demonstrated activation of the Th1-polarizing STAT5 pathway, enhanced proliferative capacity in vitro, and improved survival in mice engrafted with EBV+ IL4-producing tumors (36).

Unlike hematologic tumors, solid tumors often reside in heavily restricted areas of the body. For instance, gliomas and other central nervous system–derived tumors are difficult to treat because cells infused systemically must be able to cross the BBB in order to access the tumor. Therefore, the cell dose effectively reaching the tumor site may be significantly reduced from the dose originally administered (37). Studies have thus aimed to improve the homing capacity of T cells by expressing chemokine receptors. An ongoing phase I/II trial in which chemokine receptor CXCXR2 (chemokine C-X-C motif receptor 2) and nerve growth factor receptor (NGFR) are transduced onto TILs is recruiting patients with metastatic melanoma. This novel therapy in conjunction with preparatory lymphodepletion and chemotherapy regimens will be assessed for safety and antitumor response (NCT01740557).

Even as T-cell therapies improve in their ability to access and kill solid tumors, tumors can adapt, resulting in further immune evasion. Tumor cells can suppress an immune response by increasing their expression of key anti-inflammatory signals. Overcoming this adaptation and enabling T cells to continuously execute their antitumor effects is an extensive area of study.

Liberated: Strategies to Unleash T-cell Therapies

The balance between positive and negative signals, known as immune checkpoints, regulates T-cell activation. These immune checkpoints are important in the maintenance of normal tolerance, although tumor cells are able to take advantage of this system by dysregulating the expression of ligands that bind to the receptors on T cells, halting the immune response (38).
A number of stimulatory and inhibitory receptors have been well characterized. For example, the “stimulatory” cluster of differentiation 28 (CD28) binds its ligand and provides one of the key interactions to enable full activation of T cells. However, the “inhibitory” cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is upregulated after T-cell activation and can bind to the same cell ligand as CD28, leading to inhibitory signaling to shut down the T-cell activation (39). Early clinical investigations of immune checkpoint blockade developed antibodies to block CTLA-4 (38). Ipilimumab, a human monoclonal antibody specific to CTLA-4, improved median overall survival by 3.4 months in patients with metastatic melanoma in a randomized phase III clinical trial and is now FDA approved for the treatment of advanced melanoma (40).

More recently, the inhibitory interaction between programmed cell death protein 1 (PD-1) on T cells and programmed death-ligand 1 (PD-L1) on tumor cells has been under investigation. PD-1 is primarily responsible for the regulation of T-cell activation in peripheral tissues, making it of increased importance in the context of solid tumors. PD-L1 may be constitutively expressed in some types of tumor cells and is known to be upregulated as an evasion mechanism in other tumor cells (39). Recent clinical trials using either a blocking monoclonal antibody specific to PD-1 (41) or a monoclonal antibody blocking PD-L1 (42) demonstrated improvements in objective response rate as well as a prolonged stabilization of disease state in patients with solid tumors, including melanoma, non–small cell lung cancer, and renal cell cancer (41, 42). In September 2014, the first PD-1 inhibitor, pembrolizumab (Keytruda; Merck), was approved by the FDA for treatment of metastatic melanoma. Adoptively transferred T cells could potentially exhibit enhanced functionality if administered in conjunction with compounds capable of regulating inhibitory immune checkpoint signals. Furthermore, as strategies are developed to maximize the antitumor activity of T-cell products, evaluating the safety of these potent immune effectors will be crucial.

Improving the Safety of T-cell Therapies

Among the early successes of T cells expressing tgTCRs in treating solid tumors, there have been clinical reports of on- and off-target toxicities (43–45). A high-affinity TCR targeting MAGE-A3, in myeloma and melanoma demonstrated an unexpected cross-reactivity by recognizing titin, an unrelated protein expressed in cardiac tissue, ultimately resulting in cardiovascular toxicities and leading to the death of two patients (44). Similarly, there have been clinical reports of adverse effects following CART-cell therapy (45, 46). A patient with lung and liver metastatic colon cancer was treated with third-generation HER2-specific CAR T cells after lymphodepletion and cytokine administration, only to experience respiratory distress and cytokine release syndrome (CRS), a potentially life-threatening condition observed in patients who receive adoptive T-cell transfer. In pathologically high quantities, immunostimulatory cytokines released after T-cell activation and expansion can induce acute organ injury. In this case, either the dose of T cells administered to this lymphodeplete recipient or the resulting cytokines presumably caused lung injury from which the patient was unable to recover (45). In another study, multiple doses of mesothelin-specific CAR T cells developed with an RNA-based platform were infused to three patients with malignant pleural mesothelioma and one with pancreatic adenocarcinoma. A single patient developed an anaphylaxis reaction to the infused cells upon receipt of the third dose. This study concluded that the reaction resulted from the development of IgE antibodies specific to the CAR, warranting further study of the dosing schedule when administering repeated infusions of CAR T cells (46). To avoid such disastrous outcomes, choosing an appropriate target TAA is key, as is refining the affinity and specificity of the tgTCR or CAR, cell dose, and preparatory regimens used prior to cell therapy.

The incorporation of suicide genes into effector cells as a countermeasure has been evaluated clinically in two caspase-based systems, Herpes Simplex Virus–derived enzyme thymidine kinase (HSV-tk) and inducible caspase-9 (iC9). Both systems have demonstrated selective and efficient elimination of infused cells (47, 48). Splitting the signals needed to activate the transduced T cell between two separate CAR molecules has been used as an alternative to suicide genes. In preclinical models of prostate cancer, it was shown that T cells expressing two CARs, specific to antigens PSMA and PCMA, could be conditionally activated only in the presence of both antigens, but not by either antigen alone (49),enhancing on-tumor specificity.

Finally, administering tocilizumab, an anti-IL6 antibody, steroid therapy, or targeted immunosuppressive agents, can control CRS fairly well (50). Overall, with a means to control CRS and new systems incorporated into CAR molecules to prevent on-target off-tumor activity or eliminate overly activated cells, the safety profile of next-generation T-cell therapies has improved greatly. As we move into the future, these safety measures will enable more extensive use of CAR T-cell therapies to target a multitude of solid tumors.

The Future of T-cell Therapy

Although much of the success of T-cell transfer has been in the treatment of hematologic malignancies, therapies for solid tumors are coming of age. T-cell therapies have developed from the initial collection, expansion, and reintroduction of TILs and CTLs to the production and transfer of a number of engineered T-cell types, including those expressing tgTCRs, CARs, or BiTEs. To expand the effectiveness of T-cell therapy, addressing concerns specific to the treatment of solid tumors, such as tumor heterogeneity, antigen escape, an immunosuppressive microenvironment, and accessibility challenges, will be imperative. New combinations of TAA targeting within CAR technology as well as multimodal therapies including the combination of checkpoint inhibitors, vaccines, or other antibodies with T cells targeting TAAs and/or components of the tumor niche will be pivotal in the future.

In addition, as T-cell products have become more sophisticated, concerns about their therapeutic safety have grown as well. In the future, rational design of preclinical and clinical studies to assess any potential on-target off-tumor effects will continue to be of utmost importance. Incorporating added measures into cell products such as suicide genes, which can eliminate all transferred cells in the event of an adverse situation, will help to ensure safety. Also, studying the optimal regimens to prepare patients for cell transfer, the appropriate dose(s) and dosing schedule, and routes of administration for therapeutic T cells will be critical to ensure optimal outcomes with minimal toxicities in patients with solid tumors.

Disclaimer

This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the NIH.
Acknowledgments

The authors thank Catherine Gillespie for assistance in critical review of the article.

Grant Support

K. Fousek was supported by the National Institute of General Medical Sciences of the NIH under award numbers T32HL092332 and T32GM088129. N. Ahmed was supported by the Alliance for Cancer Gene Therapy (AGCT), Alex’s Lemonade

Stand Foundation for Childhood Cancer, and a Stand Up To Cancer – St. Baldrick's Pediatric Dream Team Translational Research Grant (S12C-AACR-DT1113). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

Received October 16, 2014; revised April 19, 2015; accepted April 22, 2015; published online August 3, 2015.

References

35. Doolittle ND, Abbey LE, Bleyer WA, Brem S, Davis TP, Dow-Duffy P, et al. New frontiers in translational research in neuro-oncology and the blood-

T-cell Therapy for Solid Cancer

www.aacjournals.org

Clin Cancer Res; 21(15) August 1, 2015

3391

Received on April 12, 2017. © 2015 American Association for Cancer Research.